Compare OKYO & IPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OKYO | IPWR |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.4M | 65.4M |
| IPO Year | 2021 | 2013 |
| Metric | OKYO | IPWR |
|---|---|---|
| Price | $1.43 | $2.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | 56.9K | ★ 113.8K |
| Earning Date | 07-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,550.55 |
| Revenue Next Year | N/A | $600.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $2.62 |
| 52 Week High | $3.20 | $9.30 |
| Indicator | OKYO | IPWR |
|---|---|---|
| Relative Strength Index (RSI) | 50.15 | 24.56 |
| Support Level | $1.29 | $2.63 |
| Resistance Level | $1.72 | $3.33 |
| Average True Range (ATR) | 0.09 | 0.24 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 26.68 | 6.60 |
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
Ideal Power Inc is engaged in the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.